CN1493275A - 丹皮酚滴丸及其制备方法 - Google Patents
丹皮酚滴丸及其制备方法 Download PDFInfo
- Publication number
- CN1493275A CN1493275A CNA031576656A CN03157665A CN1493275A CN 1493275 A CN1493275 A CN 1493275A CN A031576656 A CNA031576656 A CN A031576656A CN 03157665 A CN03157665 A CN 03157665A CN 1493275 A CN1493275 A CN 1493275A
- Authority
- CN
- China
- Prior art keywords
- paeonol
- coolant
- preparation
- polyethylene glycol
- dissolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 239000006187 pill Substances 0.000 title claims abstract description 16
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 title claims description 42
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 title claims description 42
- 238000002360 preparation method Methods 0.000 title claims description 13
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 239000002826 coolant Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 8
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- -1 liquid paraffin Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940080350 sodium stearate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- 239000008599 paeonal Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明通过应用超微粉碎和滴丸剂生产工艺技术制成的丹皮酚滴丸,可以达到提高崩解溶散速度、溶出速率和溶出度,起效迅速,提高药物稳定性,减少辅料用量,降低生产成本,携带和服用方便目的,依从性好,适合于儿童、老年人、卧床病人和吞咽困难患者服用。
Description
技术领域
本发明涉及一种医药配制品及其制备方法,具体地说是丹皮酚滴丸及其制备方法。
背景技术
丹皮酚为镇痛药。研究结果表明丹皮酚使醋酸引起的小鼠扭体反应明显减小,明显提高小鼠痛阈,明显降低小鼠直肠温度,降温作用有剂量依赖性,并在0.5小时达高峰,1-2小时内体温恢复正常。伤寒菌静脉注射引起小鼠发热,口服丹皮酚有明显解热作用,0.5小时达高峰,持续3小时,降温作用明显。对小鼠三联疫菌所致发热,丹皮酚亦有拮抗作用。丹皮酚对由角叉菜胶、蛋清、甲醛、组胺、5-羟色胺和缓激肽所致大鼠足跖肿胀,对二甲苯所致小鼠耳壳肿胀和内毒素腹腔毛细血管通透性升高均有显著的抑制作用,摘取大鼠双侧肾上腺后其抗炎作用仍存在。对大鼠肾上腺维生素C的含量无明显影响,也不能抑制由单侧切除大鼠肾上腺所致对侧肾上腺代偿增生。其抗炎作用不依赖于垂体-肾上腺系统,也无可的松样作用。丹皮酚抑制炎性组织中PGE2的生物合成,抑制角叉菜胶胸膜炎多形核白细胞移行,内毒素腹腔毛细血管通透性升高和对脂氧酶活性均有显著的抑制作用,丹皮酚还能防止小鼠应激性溃疡及抑制大鼠胃液分泌,并有一定的解痉作用。其抗炎特点有别于非甾体抗炎药。动物试验表明,丹皮酚按75~100mg/kg腹腔注射连续5日,显著抑制豚鼠Forssman皮肤血管炎反应,大鼠反向皮肤过敏反应、大鼠主动和被动Arthus型足跖肿胀。每日50~200mg/kg腹腔注射对羊红细胞、牛血清蛋白诱导的小鼠迟发型足跖肿胀,对2,4-二硝基氟苯引起的小鼠接触性皮炎均有明显的抑制作用,即对II、III和IV型变态反应均有抑制作用。
丹皮酚口服吸收,用14C标记丹皮酚,实验证明大鼠灌胃16.6mg/kg,20分钟后血中浓度达到最高水平,然后急速下降,给药3小时后以肝脏分布最高,依次为肾、脾和肺。给药24小时内尿中和粪中排除率分别为89%和5%,从尿中检出丹皮酚及其代谢产物2,4-二羟基乙酰苯、2,5-二羟基-4-甲氧基苯乙酮3种物质分别占11.4%、21.0%、67.6%。证实丹皮酚口服能迅速吸收、代谢和排泄。
目前上市销售的只有丹皮酚糖衣片,临床用于发热、头痛、神经痛、肌肉痛、风湿性关节炎和类风湿性关节炎。
丹皮酚有特异臭,味微辣,在水中不溶,丹皮酚糖衣片的崩解较慢,溶出度和溶出速率较低,稳定性较差,儿童、老年人、卧床患者或吞咽困难患者服用不方便,依从性较差,影响了丹皮酚治疗作用的发挥。
本发明就是通过应用超微粉碎技术和滴丸制剂工艺技术制成丹皮酚滴丸剂,从而克服丹皮酚片的以上缺陷,使丹皮酚的治疗作用得以充分发挥。
发明内容
通过应用超微粉碎技术和滴丸制剂工艺技术制成的丹皮酚滴丸不仅具有崩解溶散快,溶出度和溶出速率提高,质量稳定,药丸体积小,携带和服用方便,起效迅速,依从性好,特别适合儿童、卧床病人、老年人和吞咽困难患者服用的特点,而且还具有生产条件和生产设备简单,生产成本低,辅料用量减少的优点,充分体现了新药研究开发以人为本的精神。
为达到上述目的,本发明采用以下技术方案:将1重量份经超微粉碎的丹皮酚细粉加入至1~10重量份熔融的基质中,充分混匀,滴制法在冷却剂中冷凝成丸,除冷却剂,干燥,即得。
本发明中丹皮酚的化学名称为2-羟基-4-甲氧基-苯乙酮,分子式为C9H10O3,分子量为166.18,结构式为:
本发明中的基质包括但不限于聚乙二醇6000、聚乙二醇4000、聚乙二醇1500、聚乙二醇1000、硬脂酸钠、甘油明胶、泊洛沙姆、硬脂酸、单硬脂酸甘油酸、虫蜡等。
本发明中的冷却剂包括但不限于二甲基硅油、液体石蜡、植物油、水、乙醇溶液等。
下面经过检测对照说明本发明的有益效果
一、检测指标及方法
1.崩解(溶散)时限:照崩解时限检查法(中国药典2000年版二部附录XA)检查。
2.溶出速率:取样品,照溶出度测定法(中国药典2000年版二部附录XC第一法),以水900ml为溶剂,转速每分钟100转,依法操作,经5、10、20、30和45分钟时,取溶液10ml,滤过,精密量取续滤液适量,加水稀释制成每1ml中含丹皮酚6μg的溶液,照分光光度法(中国药典2000年版二部附录IV A)测定,在275nm的波长处测定吸收度,按C9H10O3的吸收系数(E1cm 1%)为862计算溶出量。
二、市售丹皮酚片检测结果
1.崩解时间:51分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 21.2 32.3 52.5 61.3 72.5
三、实例1样品检测结果
1.溶散时间:8分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 54.6 88.3 99.2 99.5 98.4
四、实例2样品检测结果
1.溶散时间:10分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 51.18 5.2 98.3 99.6 99.7
五、实例3样品检测结果
1.溶散时间:7分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 53.5 84.2 98.6 97.3 99.2
六、实例4样品检测结果
1.溶散时间:10分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 51.3 85.3 98.6 98.9 99.2
七、实例5样品检测结果
1.溶散时间:12分钟
2.溶出速率:
时间(分钟) 5 10 20 30 45
溶出度(%) 45.6 78.5 86.2 99.2 100.1
八、实例6样品检测结果
1.溶散时间:16分钟
2.溶出速率
时间(分钟) 5 10 20 30 45
溶出度(%) 41.3 62.4 89.5 98.6 99.7
具体实施方式
一、实例1
处方:
丹皮酚 5g
聚乙二醇6000 15g
制成 1000粒
制法:取经超微粉碎过200目筛的丹皮酚细粉加入至熔融的聚乙二醇6000基质中,搅匀,以二甲基硅油为冷却剂,滴制法制丸,干燥,即得。
二、实例2
处方:
丹皮酚 5g
聚乙二醇4000 15g
制成 1000粒
制法:取经超微粉碎过200目筛的丹皮酚细粉加入至熔融的聚乙二醇4000基质中,搅匀,以二甲基硅油为冷却剂,滴制法制丸,干燥,即得。
三、实例3
处方:
丹皮酚 5g
聚乙二醇6000 5g
聚乙二醇4000 10g
制成 1000粒
制法:取经超微粉碎过200目筛的丹皮酚细粉加入至熔融的聚乙二醇4000和聚乙二醇6000混合基质中,搅匀,以二甲基硅油为冷却剂,滴制法制丸,干燥,即得。
四、实例4
处方:
丹皮酚 5g
单硬脂酸甘油酯 15g
制成 1000粒
制法:取经超微粉碎过200目筛的丹皮酚细粉加入至熔融的单硬脂酸甘油酯基质中,混匀,以冰水为冷却剂,滴制法制丸,干燥,即得。
五、实例5
处方:
丹皮酚 5g
聚乙二醇6000 10g
泊洛沙姆 5g
制成 1000粒
制法:取经超微粉碎过200目筛的丹皮酚细粉加入至熔融的聚乙二醇6000和泊洛沙姆混合基质中,搅匀,以二甲基硅油为冷却剂,滴制法制丸,干燥,即得。
六、实例6
处方:
丹皮酚 5g
单硬脂酸甘油酯 15g
泊洛沙姆 1g
制成 1000粒
制法:取丹皮酚和泊洛沙姆经超微粉碎过200目筛的混合细粉加入至熔融的单硬脂酸甘油酯基质中,混匀,以冰水为冷却剂,滴制法制丸,干燥,即得。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031576656A CN1493275A (zh) | 2003-09-06 | 2003-09-06 | 丹皮酚滴丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA031576656A CN1493275A (zh) | 2003-09-06 | 2003-09-06 | 丹皮酚滴丸及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1493275A true CN1493275A (zh) | 2004-05-05 |
Family
ID=34240892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA031576656A Pending CN1493275A (zh) | 2003-09-06 | 2003-09-06 | 丹皮酚滴丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1493275A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823747B (zh) * | 2005-02-25 | 2010-07-21 | 山东绿叶天然药物研究开发有限公司 | 丹皮酚薄膜衣滴丸及其制备方法 |
CN1872037B (zh) * | 2005-06-01 | 2010-09-29 | 天津天士力制药股份有限公司 | 一种丹皮酚滴丸及其制备方法 |
-
2003
- 2003-09-06 CN CNA031576656A patent/CN1493275A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823747B (zh) * | 2005-02-25 | 2010-07-21 | 山东绿叶天然药物研究开发有限公司 | 丹皮酚薄膜衣滴丸及其制备方法 |
CN1872037B (zh) * | 2005-06-01 | 2010-09-29 | 天津天士力制药股份有限公司 | 一种丹皮酚滴丸及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1493275A (zh) | 丹皮酚滴丸及其制备方法 | |
CN1839836A (zh) | 一种制备尼可地尔片的方法 | |
CN1850167A (zh) | 一种消渴降糖滴丸及其制备方法 | |
CN101028348A (zh) | 一种中药胶囊及其制备方法和质量控制方法 | |
CN1939377A (zh) | 一种中药组合物及其制备工艺和在制药中的应用 | |
CN1493290A (zh) | 阿魏酸哌嗪滴丸及其制备方法 | |
CN1493295A (zh) | 齐墩果酸滴丸及其制备方法 | |
CN1562001A (zh) | 卡络磺钠滴丸及其制备方法 | |
CN1493298A (zh) | 人参茎叶总皂苷滴丸及其制备方法 | |
CN1528321A (zh) | 天麻素滴丸及其制备方法 | |
CN1528287A (zh) | 石吊兰素滴丸及其制备方法 | |
CN1493288A (zh) | 汉防已甲素滴丸及其制备方法 | |
CN1602860A (zh) | 富马酸氯马斯汀滴丸及其制备方法 | |
CN1299673C (zh) | 盐酸氨溴索滴丸及其制备方法 | |
CN1493274A (zh) | 香草醛滴丸及其制备方法 | |
CN1493296A (zh) | 雪胆素滴丸及其制备方法 | |
CN1528272A (zh) | 鹤草酚滴丸及其制备方法 | |
CN1493287A (zh) | 石杉碱甲滴丸及其制备方法 | |
CN1526393A (zh) | 盐酸肼屈嗪滴丸及其制备方法 | |
CN1562027A (zh) | 盐酸曲美他嗪滴丸及其制备方法 | |
CN1528318A (zh) | 冰凉花苷滴丸及其制备方法 | |
CN1616054A (zh) | 一种祖师麻冻干粉针剂及其制备方法 | |
CN1582939A (zh) | 盐酸二氧丙嗪滴丸及其制备方法 | |
CN1686358A (zh) | 一种黄瑞香粉针剂及其制备方法 | |
CN1543961A (zh) | 奥沙西泮滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |